Immusmol
Alban Bessede, PhD, is a highly experienced professional in the field of immunology and biotechnology. Currently serving as the Founder and Chief Executive Officer of Nobel Therapeutics since February 2023, Alban also holds similar positions at Explicyte and ImmuSmol, both established in March 2016 and August 2012, respectively. Explicyte focuses on preclinical and translational research in Immuno-Oncology, providing services such as cell-based assays and patient sample analysis. ImmuSmol specializes in facilitating the visualization and quantification of small molecules through immunoassays. Alban’s academic background includes a post-doctoral fellowship at the University of New South Wales and a PhD in Immunology from the Università per Stranieri di Perugia, where research centered on the immune response and tryptophan metabolites.
This person is not in any teams
Immusmol
Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies). > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.